ライフサイエンスコーパス: patency

1 eling of follicular epithelium (also called 'patency').

2 RA was found to be patent in 24 cases (84.8% patency).

3 and EC-specific proteins and maintain graft patency.

4 rements and implications for long-term graft patency.

5 e showing obstruction and the second showing patency.

6 d a preservation of the entire vascular tree patency.

7 conduit function and possibly improve graft patency.

8 e muscles of respiration and maintain airway patency.

9 nical challenge in determining tibial artery patency.

10 ntity; increased Eph-B activity improves AVF patency.

11 clot stability and maintaining blood vessel patency.

12 recoil, when it did occur, did not influence patency.

13 inophil-dependent effector response prior to patency.

14 ic recoil and determine its effect on access patency.

15 associations are explained by reduced airway patency.

16 isted patency, and 89% (74-93) had secondary patency.

17 a improved medium-term arteriovenous fistula patency.

18 al and uterine morphology and fallopian tube patency.

19 he primary end point was 3-year angiographic patency.

20 significantly influenced long-term RA graft patency.

21 rinolysis to physiologically maintain vessel patency.

22 motoneurons important for maintaining airway patency.

23 nd/MRI were used subsequently to document PV patency.

24 c evidence of ostium patency and canalicular patency.

25 lesion revascularization and loss of primary patency.

26 activation of canonical Wnt causes PF-suture patency.

27 ontributes to awakening and restoring airway patency.

28 lation might be required to increase luminal patency.

29 Primary endpoint was arterial occlusion/patency.

30 by the majority of infections do not achieve patency.

31 The primary outcome was primary stent patency.

32 tongue, is required to maintain upper airway patency.

33 his could reflect variable degrees of airway patency.

34 axis alters venous remodeling to improve AVF patency.

35 gesting a need to improve AVF maturation and patency.

36 BCL11B in the maintenance of cranial suture patency.

37 ential translational strategy to improve AVF patency.

38 ffectiveness but is also dependent on airway patency.

39 At 12 months, 28% (17-40) had primary patency, 38% (26-51) had primary assisted patency, and 8

40 to 3.8; P=0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients;

41 Outcomes at 1 year were primary patency, 63.1% (95% CI, 57.3-68.6); repeat revasculariza

42 , 63% (95% CI 47-72) of patients had primary patency, 73% (57-81) had primary assisted patency, and 9

43 TA per the Kaplan-Meier estimate for primary patency (89.0% versus 65.0% at 365 days; log-rank P<0.00

44 on to Inhibit Restenosis and Maintain Vessel Patency-A Pilot Study of Anti-Restenosis Treatment) was

45 Status of graft patency across time was analyzed by longitudinal nonline

46 Purpose To assess patency-adjusted costs of endovascular dialysis access m

47 Conclusion Patency-adjusted payments for hemodialysis access mainte

48 Secondary end points included anatomic patency, adverse event rate, and return to operating roo

49 able antithrombotic agents to restore vessel patency after arterial occlusion.

50 VF abandonment and interventions to maintain patency after maturation may be more frequent with assis

51 are long-term survival, morbidity, and graft patency after multiarterial versus single-arterial CABG.

52 f GpIbalpha-VWF interactions restores vessel patency after occlusive thrombosis by specifically disag

53 aphic (US) nephrostograms to assess ureteral patency after percutaneous nephrolithotomy (PCNL) in thi

54 occurrence does not influence access primary patency after PTA.

55 r PTX, Cook, IN) has shown to improve vessel patency after superficial femoral angioplasty.

56 us methods that can be used to measure nasal patency, airflow and resistance, mainly peak nasal inspi

57 Restoration of vessel patency alone failed to reverse tubulointerstitial damag

58 in the poststenotic kidney, restoring vessel patency alone is insufficient to recover kidney function

59 At 12 months, we found higher primary patency among patients receiving regional versus local a

60 use was also associated with improved lesion patency among patients undergoing infrapopliteal angiopl

61 At 12 months, the rate of primary patency among patients who had undergone angioplasty wit

62 he Kolliker-Fuse (KF) maintains upper airway patency and a normal respiratory pattern.

63 restoring epicardial infarct-related artery patency and achieving microvascular reperfusion as early

64 data through 2014, postintervention primary patency and aggregate payments associated with maintenan

65 may be useful for predicting long-term graft patency and assessing grafts intraoperatively in patient

66 12 months and endoscopic evidence of ostium patency and canalicular patency.

67 conducted to assess whether DES also improve patency and clinical outcome of infrapopliteal lesions.

68 The RAPCO trials (Radial Artery Patency and Clinical Outcomes) were designed to compare

69 thrombi resulting in fast restoration of MCA patency and consequently reduced cerebral infarct sizes

70 tment in P2 was a predictor of worse primary patency and F-MALE and therefore close and long follow-u

71 ug-coated balloon (DCB) angioplasty, primary patency and freedom from target lesion revascularization

72 lial cells plays a vital role in maintaining patency and homeostasis.

73 ing GpIbalpha-VWF inhibitors restored vessel patency and improved outcome in a mouse model of ischemi

74 c arteries (BITA) have demonstrated superior patency and improved survival in patients undergoing cor

75 data may be helpful in predicting long-term patency and in the decision of whether to revise a quest

76 e SXT-THV, as demonstrated by improved valve patency and increased transfemoral access safety.

77 Rates of 1-year FitzGibbon grade A patency and intraoperative revision were compared based

78 vened segments, both of which may jeopardize patency and lead to recurrent symptoms, functional impai

79 and molecular effects of statins on fistula patency and maturation remain poorly understood.

80 s improve experimental arteriovenous fistula patency and maturation, indicating that additional clini

81 of statin therapy on primary murine fistula patency and maturation.

82 erform and are capable of demonstrating both patency and obstruction of the ureter.

83 nctive myocardial features, such as vascular patency and pump function.

84 oms partially improved with a combination of patency and reflux on syringing.

85 y play an important role in regulating A-TEV patency and regeneration, possibly by regulating the inf

86 iker-Fuse nucleus (KF) controls upper airway patency and regulates respiration, in particular the ins

87 high capillary density, diminished vascular patency and severe cardiac dysfunction.

88 years included secondary outcomes of primary patency and target lesion revascularization (TLR) estima

89 TTP was inversely correlated with vascular patency and verteporfin uptake, suggesting interstitial

90 ts were evaluated with objective (anatomical patency) and subjective (symptomatic cure) success rates

91 ry patency, 38% (26-51) had primary assisted patency, and 89% (74-93) had secondary patency.

92 ry patency, 73% (57-81) had primary assisted patency, and 97% (85-98) had secondary patency, with mos

93 , with late luminal enlargement, side-branch patency, and development of a signal-rich, low-attenuati

94 blood-brain barrier function, microvascular patency, and the rerouting of blood to hypoperfused brai

95 and as good an indication of objective nasal patency as formal rhinomanometry and has the advantage t

96 s include serial duplex ultrasound for stent patency assessment.

97 by primary, primary assisted, and secondary patencies at 6 months.

98 relor added to standard aspirin improves SVG patency at 1 year after CABG.

99 tly improved both primary and functional AVF patency at 1 year and is cost-effective.

100 ffectiveness outcome was venographic primary patency at 1-year.

101 reated with the helical stent who maintained patency at 12 and 24 months was 80% and 72%, respectivel

102 Primary patency at 12 months (360 +/- 30 days) was achieved in 7

103 e primary effectiveness endpoint was primary patency at 12 months assessed by Kaplan-Meier.

104 coated balloon resulted in a rate of primary patency at 12 months that was higher than the rate with

105 primary effectiveness end point was primary patency at 12 months.

106 ndings on primary, functional, and secondary patency at 12 months; reinterventions; and additional ac

107 dimensions and function, and aortic size and patency at 14.1 +/- 1.2 months and 33.6 +/- 9.6 months i

108 Primary patency at 3 months was higher in the BPB group than the

109 e primary endpoint was arteriovenous fistula patency at 3 months.

110 ia, regional anesthesia improves primary AVF patency at 3 months.

111 te (primary, primary assisted, and secondary patency at 6 and 12 months), (2) improvement of quality

112 nhibitor treatment effectively improved TEVG patency at 6 mo compared to the untreated control group

113 Sustained device patency at 6 months was confirmed by left-to-right shunt

114 The secondary end point was anatomic patency based on nasolacrimal syringing and categorized

115 secondary patency, with most loss of primary patency because of thrombosis.

116 id not show significant differences in graft patency between groups.

117 revealed no significant difference in graft patency between the 2 BITA configurations.

118 x; (b) >50% patent but some reflux; (c) some patency but >50% reflux; or (d) nonpatent, 100% reflux.

119 e prevalence of tibial artery and pedal arch patency by angiography in these patients.

120 mours in mice improved the duration of stent patency by delaying tumour ingrowth.

121 Primary patency by Kaplan-Meier analysis at 12 months (360 days)

122 results suggest that rapamycin improves AVF patency by reducing early inflammation and wall thickeni

123 to the artery, potentially improving vessel patency by reducing restenosis.

124 study was to determine whether upper airway patency can be improved using chemogenetic approach by d

125 ne magnetic resonance enterography (MRE) and patency capsule, clinical or biomarker assessment every

126 Functional tests examining ET patency confirmed a reduced clearing ability in the hete

127 e preservation strategies and intraoperative patency control have important roles in the prevention o

128 In contrast, saphenous vein graft patency declined over time and similarly in patients wit

129 tiveness end point was target-lesion primary patency, defined as freedom from clinically driven targe

130 The primary efficacy end point was primary patency, defined as freedom from restenosis or clinicall

131 utaneous transluminal angioplasty or loss of patency during 12-month follow-up.

132 enioglossus muscle activity and upper airway patency during sleep.

133 mycin was associated with improved long-term patency, enhanced early AVF remodeling and sustained red

134 plete recovery, aesthetic, functional (nasal patency, eye closure, speech and swallowing) and psychol

135 false lumen thrombosis (FLT) and false lumen patency (FLP) was determined and the effect on post-TEVA

136 model supports normal blood flow and vessel patency for 24 weeks.

137 deled probabilities of primary and secondary patency for each access type, with success modified by a

138 tents and drug-coated balloons have improved patency for moderate-length lesions, whereas others allo

139 The 24-month assessments included primary patency, freedom from clinically driven target lesion re

140 g the small bowel with confirmed small bowel patency from three tertiary medical centres in Israel.

141 higher payments, respectively, for the same patency gain compared with radiologists.

142 Unadjusted payments per year of access patency gain were compared across physician specialty.

143 ing chest compressions, intrathoracic airway patency greatly affects the delivered ventilation.

144 lue of microvesicles (MVs) for midterm graft patency has never been tested.

145 iaphragmatic contraction that preserves lung patency has yet to be explored.

146 e relationship between survival and vascular patency immediately after TIPS.

147 and CC angiographic imaging regarding graft patency in 114 of 115 grafts identified with CC angiogra

148 olysis In Myocardial Infarction flow grade 3 patency in 15% of patients with acute myocardial infarct

149 Improved patency in a porcine vessel for 18 d is demonstrated whi

150 ate platelet-rich thrombi and restore vessel patency in acute thrombotic disorders such as ischemic s

151 Maintaining good blood patency in catheterized rats is not difficult.

152 Conclusion: Maintaining good blood patency in catheterized rats is not difficult.

153 Contrast-enhanced US demonstrated ureteral patency in eight studies and obstruction in two.

154 Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Gr

155 bypass grafting because they have excellent patency in patients with and without diabetes even after

156 creasingly used to maintain long-term venous patency in patients with iliofemoral venous outflow obst

157 proof, and demonstrated biocompatibility and patency in rabbit eyes.

158 Herein, successful patency in the deployment of an ~2 mm diameter graft int

159 m in maintaining perfusion and microvascular patency in the ischemic penumbra that is coordinated by

160 membrane receptor mediating JH regulation of patency in the red flour beetle.

161 Poor flow patency is an unresolved issue in grafts, particularly t

162 Graft patency is one of the major determinants of long-term ou

163 artery stenosis, we hypothesized that graft patency is worse in patients with than without diabetes.

164 tion of liver burden and delayed blood-stage patency, leading to a disease outcome different from tha

165 sponse that influences vessel remodeling and patency, limiting long-term benefits of cardiovascular i

166 n AVF outcomes, including functional primary patency loss (requiring intervention after achieving AVF

167 ons and the likelihood of functional primary patency loss and frequency of postmaturation interventio

168 icantly increased risk of functional primary patency loss compared with patients who had unassisted A

169 The rate of stent occlusion (patency loss) and venous thromboembolism varies substant

170 versus PTA with significantly higher primary patency, lower CD-TLR, and similar functional status imp

171 Intuitively, sustained vessel patency may be considered as a main variable related to

172 ocardial infarction; superior infarct artery patency, no reocclusions, and 1% mortality resulted.

173 anch occlusion (ABO, n=17) and atrial branch patency (non-ABO, n=92).

174 ]; Asp/Pla) therapy achieved nearly half the patency observed in the SCID/bg mouse (NK Ab: 0.356 +/-

175 FitzGibbon grade A patency occurred significantly less often in grafts with

176 hs), primary patency was 94%, with secondary patency of 95.3%.

177 interactions on EAE pathogenesis and on the patency of a model blood-brain barrier to T-cell transce

178 in vitro and promote endothelialization and patency of acellular tissue-engineered vessels (A-TEVs)

179 amine the influence of diabetes on long-term patency of bypass grafts.

180 about the influence of diabetes on long-term patency of bypass grafts.

181 thesis, diabetes did not influence long-term patency of bypass grafts.

182 uct cancer patients and results in prolonged patency of hilar bile ducts, a trend for longer survival

183 s, diabetes was associated with higher early patency of ITA grafts (odds ratio: 0.63; 95% confidence

184 e limits: 0.43 to 0.91; p = 0.013), but late patency of ITA grafts was similar in patients with and w

185 Within 24 hours, patency of radial artery was checked by Doppler using re

186 nificance of the R-Ras-Akt signaling for the patency of regenerating blood vessels.

187 Early and late patency of saphenous vein grafts were similar in patient

188 The patency of target vessels is important for survival.

189 oading based on the contractility state, the patency of the actin cytoskeleton, and the connections i

190 Post-decellularization patency of the cavernosal arteries for future use in res

191 gas and oxygenation parameters and maintain patency of the fetal circulation.

192 icles, which play a crucial role to maintain patency of the narrow sites of CSF passage during brain

193 omes) were designed to compare the long-term patency of the radial artery (RA) with that of the right

194 consumption rate as a main predictor of the patency of the revascularized bioengineered livers (rBEL

195 day 3: postmortem examination confirmed the patency of the stent.

196 The primary efficacy end point was primary patency of the target lesion at 12 months (defined as fr

197 dysfunction, it is critical to determine the patency of the transplant vasculature to guide clinical

198 hy, and ulnar frame count to investigate the patency of the ulnopalmar arches, as well as handgrip st

199 Imaging data on the patency of the vertebral arteries and posterior communic

200 Primary end point was 6-month primary binary patency of treated lesions, defined as </=50% stenosis o

201 Conclusion Persistent patency of vasculature within the coagulated zone from I

202 Morphologic parameters evaluated were IMA patency, origin of the IMA in relation to the aneurysm s

203 ng provides real-time evaluation of vascular patency, oxygenation, and nanoparticle distributions.

204 Primary patency per Kaplan-Meier estimates at day 365 was 82.3%

205 The high rate of MPV patency post-TIPS placement suggests flow reestablishmen

206 hronic obstructive pulmonary disease, airway patency problems, and prolonged mechanical ventilation.

207 hronic obstructive pulmonary disease; airway patency problems; or prolonged mechanical ventilation.

208 nduit is associated with the highest 10-year patency rate (>90%), saphenous vein grafts - the most co

209 Good patency rate (100%) with self-expandable metallic stents

210 imary aim of the trial is to compare (1) the patency rate (primary, primary assisted, and secondary p

211 ies of steel-alloy stents described variable patency rate across indications.

212 Eighty-nine percent MPV patency rate and 82% survival were achieved at 5 years.

213 as an independent predictor of worse primary patency rate and Freedom from major adverse limb events

214 The 1-year primary patency rate for the entire group was 84.0%.

215 nclear whether the well-documented increased patency rate of arterial grafts translates into clinical

216 The 20-year patency rate of RA grafts is good, and not inferior to t

217 The 10-year patency rate of the RA is significantly higher than that

218 ntry technique is associated with a very low patency rate regardless of the type of stent used.

219 eved without surgical repair, with a carotid patency rate superior to published data after surgical c

220 The cumulative 3-year primary patency rate was 80.5% (95% CI, 73.0%-88.0%) for acute t

221 TA, P=0.025 for superiority) and the primary patency rate was significantly higher with DCB (76.3% fo

222 On the basis of the high primary patency rate, absence of stent fracture, and significant

223 drug-eluting stents (DES) have shown better patency rates and are standard practice nowadays.

224 opliteal lesions, DES provide better 6-month patency rates and less amputations after 6 and 12 months

225 her the "best of both worlds": the excellent patency rates and survival benefits associated with the

226 Patency rates at 12 months suggest comparable effectiven

227 The primary patency rates at 6 and 12 months were 67% and 50%.

228 The secondary patency rates at 6 and 12 months were 75% and 67%.

229 believed to improve the graft longevity and patency rates at distal graft anastomoses.

230 e past decade have reported similar mid-term patency rates between vein grafts and arterial grafts wh

231 , BPB significantly improved 3 month primary patency rates for arteriovenous fistulae.

232 oropopliteal interventions reported superior patency rates for both strategies compared to standard b

233 Venographic patency rates for the nonthrombotic and chronic post-thr

234 The 12-month primary patency rates in the Viabahn and BMS groups were: intent

235 ith thrombosis-free patency (thrombosis-free patency rates of 54%, 38%, and 26% for low, middle, and

236 nterior descending artery alongside the good patency rates of drug-eluting stents, which outlive saph

237 dence shows that arterial grafts have better patency rates than saphenous vein grafts (SVGs) in coron

238 nstrated that it provides superior long-term patency rates to the saphenous vein in most situations.

239 Six-month patency rates were 48.0% for DES and 35.1% for PTA+/-BMS

240 mulative 1-, 2-, 3-, 5-, and 10-year primary patency rates were 64%, 59%, 54%, 45%, and 45%, respecti

241 Clinical outcomes and patency rates were assessed at 1, 6, and 12 months.

242 However, long term patency remains limited by the development of vascular i

243 going CABG surgery in the past decade, graft patency remains the 'Achilles' heel' of this procedure.

244 onal stent placement) and long-term (primary patency, repeat revascularization, major amputation, all

245 o open surgery, with good 12-month follow-up patency results comparable to surgery.

246 ng: factors related to late events and Graft patency) study that enrolled 330 patients undergoing ele

247 Preprocedural patency tests have thus no added benefit to prevent isch

248 er, more convenient way to evaluate ureteral patency than fluoroscopy.

249 s were fractional flow reserve during vessel patency, the quantitative intracoronary ECG ST-segment e

250 interstitium, restoring the tubular luminal patency; this was followed by degradation of interstitia

251 a negative association with thrombosis-free patency (thrombosis-free patency rates of 54%, 38%, and

252 primary effectiveness end point was primary patency through 12 months.

253 ef at final follow-up, and primary/secondary patency through 5 years.

254 and prolonged primary arteriovenous fistula patency through day 42 (P<0.05 versus control for all me

255 Blood contacting surfaces maintain their patency through physico-chemical properties of a functio

256 ee vaccinees (3/14, 21%), and delays time to patency through substantial reduction of liver-stage par

257 The EVFW is an intraoperative gauge of patency through the trabecular outflow pathway.

258 oMimics 3D helical stent, there was improved patency to 2 years.

259 ant distal biliary obstruction with superior patency to plastic stents.

260 DCB resulted in higher primary patency versus PTA (82.2% versus 52.4%; P<0.001).

261 of halofuginone dramatically increased lumen patency via adaptive remodeling and selective inhibition

262 - 1.8 months, the success rate of anatomical patency was 100% (27/27) and the success rate of symptom

263 At 3-month follow-up, primary venous patency was 100% in the ultrasound-assisted catheter-dir

264 Internal carotid artery patency was 100%, while the overall final angiographic o

265 Six-month primary patency was 34.8% in grafts and 47.1% in fistulas.

266 Duplex ultrasound patency was 84.6% for DA+DCB, 81.3% for DCB (P=0.78), an

267 versus SV comparison, the estimated 10-year patency was 85% for the RA versus 71% for the SV (hazard

268 ersus RITA comparison, the estimated 10-year patency was 89% for RA versus 80% for free RITA (hazard

269 of 17.1 months (range: 1-70 months), primary patency was 94%, with secondary patency of 95.3%.

270 Patency was a secondary end point.

271 At 2 years, primary patency was achieved in 90.2% (95% confidence interval [

272 e accuracy of CT for the assessment of graft patency was also analyzed.

273 FitzGibbon grade A patency was also inversely correlated with increasing PI

274 Preservation of vascular patency was assessed by imaging, cell and antigen remova

275 tive anticoagulation was standard and venous patency was assessed by routine computed tomographic sca

276 iation of variables with the risk of loss of patency was assessed by using a Cox proportional hazards

277 Subclavian vein patency was assessed in 26 patients.

278 Nevertheless, secondary patency was close to 100%, and long-term survival was go

279 red TTF and/or PI in 2738 grafts, and 1-year patency was determined in 1710 (62.5%) of these grafts.

280 Primary patency was equivalent for supraceliac, infrarenal, and

281 Access patency was estimated by using Kaplan-Meier survival met

282 The patency was evaluated by Kaplan-Meier analysis.

283 US and fluoroscopic assessments of ureteral patency was evaluated by using a Clopper-Pearson exact b

284 Venous internal lumen patency was maintained for the duration of implantation.

285 r the index procedure, target-lesion primary patency was maintained more often in participants who ha

286 th M1- and M2-type macrophages; however, AVF patency was reduced.

287 ITA graft patency was stable over time and similar in patients wit

288 l versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized con

289 durations of the primary and secondary stent patency were 114.7+/-15.1 and 146.4+/-21.2 days, respect

290 Kaplan-Meier estimates of primary patency were 79% and 80% for DES and DCB at 12 months (p

291 At 1 year, primary and secondary patency were 96% and 99% for nonthrombotic, 87% and 89%

292 dicare payments for each incremental year of patency were as follows: $71 000 for radiologists, $89 0

293 Differences in airway patency were associated with huge changes in delivered v

294 with DCB showed significantly higher primary patency when compared with PTA (78.9% vs. 50.1%; p < 0.0

295 iod, during which we analyzed hepatic artery patency with Doppler ultrasound at 1, 3, 6, and 12 month

296 ng with Ephrin-B2/Fc showed improved fistula patency with less wall thickness.

297 successful restoration of epicardial vessel patency with primary percutaneous coronary intervention,

298 isted patency, and 97% (85-98) had secondary patency, with most loss of primary patency because of th

299 ompared with portal veins, and only arterial patency within an ablation zone was related to local tum

300 ic model, hiPSC-derived TEVGs show excellent patency without luminal dilation and effectively maintai